Glucagon-Like Peptide-1
About Glucagon-Like Peptide-1
Glucagon Like Peptide 1 (GLP 1) refers to a class of incretin hormones and corresponding receptor agonist drugs used to treat type 2 diabetes and obesity, with ongoing development in obesity programs and combination therapies.
Trend Decomposition
Trigger: Advancements in incretin biology and demand for non insulin therapies for type 2 diabetes and obesity.
Behavior change: More patients and clinicians adopt GLP 1 receptor agonists as first line injectable therapies and for weight management, increasing patient adherence and monitoring.
Enabler: Pharmaceutical innovation, new formulations (weekly/daily injections, oral formats in development), and expanding indications including obesity.
Constraint removed: Improved delivery options and better tolerability profiles reduce barriers to adoption compared to prior injectable therapies.
PESTLE Analysis
Political: Regulatory approvals and payer coverage shape access to GLP 1 therapies.
Economic: High cost and long term value considerations influence adoption and reimbursement.
Social: Increasing awareness of obesity and metabolic health drives demand for effective GLP 1 therapies.
Technological: Advances in peptide engineering and delivery systems enable longer acting formulations and potential oral options.
Legal: Intellectual property and patent timelines affect market dynamics and competition.
Environmental: Manufacturing and supply chain sustainability considerations apply to biologics.
Jobs to be done framework
What problem does this trend help solve?
Provide effective, non insulin therapies for type 2 diabetes and obesity with potential weight loss benefits.What workaround existed before?
Reliance on insulin, other oral antidiabetics with varying efficacy and tolerability, and non drug lifestyle interventions.What outcome matters most?
Efficacy in glycemic control and weight loss with convenient dosing and favorable safety profile.Consumer Trend canvas
Basic Need: Sustainable metabolic health management.
Drivers of Change: Rising obesity prevalence, demand for non insulin therapies, and improved drug delivery.
Emerging Consumer Needs: Simpler dosing, meaningful weight reduction, minimal side effects.
New Consumer Expectations: Proven real world effectiveness, payer coverage, and convenient administration.
Inspirations / Signals: Positive trial results, broader label expansions, and combination therapy interest.
Innovations Emerging: Long acting formulations, oral GLP 1 candidates in development, and fixed dose combinations.
Companies to watch
- Novo Nordisk - Leader in GLP 1 therapies with Ozempic, Rybelsus, and Wegovy indications; dominant market player.
- Eli Lilly - Developed and marketed dulaglutide (Trulicity) and engaged in GLP 1 obesity programs.
- Sanofi - Marketed lixisenatide (Lyxumia) and participates in incretin therapy development.
- Boehringer Ingelheim - Collaborations in diabetes and metabolic disease where GLP 1 therapies are part of broader portfolios.